Latest news

Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe

Les projets «Hello Mask» et «Le 5ème mur» remportent le Challenge Debiopharm-Inartis 2016 sur la Qualité de Vie des Patients

GenePOC announces setup of an extensive network of commercial partners across Europe for Distribution

Debiopharm International SA Reaches Important Development Milestones for its Staphylococcus-selective antibiotic Debio 1450

Debiopharm International SA Announces Clinical Collaboration with the Merck-Pfizer Alliance in Cancer Immunotherapy

Coorpacademy raises 10 million euros and achieves one of the most important fundraisings in the European EdTech sector

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2016 JCA-Mauvernay Award

Debiopharm invests double digit millions in the Canadian startup GenePOC, specialized in the development of rapid diagnostic tests

Debiopharm acquires a majority holding in the Canadian start-up GenePOC